ADMA Biologics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from ADMA Biologics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every $100 of sales, $65 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $107 tied up three years earlier. More money tied up than 97% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 93% of Healthcare companies in United States.
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $56 of operating cash. Lower than 92% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$56Over the last 3 years, every $100 of reported profit came with $56 of operating cash.
Lower than 92% of Healthcare companies in United States.
Self-Funding Ratio
4.9×Over the last 3 years its own operating cash covered its investment spending (capex) 4.9 times.
Higher than 86% of Healthcare companies in United States.
Cash Locked Ratio
$65For every $100 of sales, $65 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $107 tied up three years earlier.
More money tied up than 97% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$60Sales grew 231% in 3 years; of every extra $100 of sales, $60 became extra profit.
Higher than 72% of Healthcare companies in United States.
Asset Productivity Ratio
+231% / +79%In 3 years sales changed by +231% while total assets changed by +79%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
17.9×Debt due within a year is covered 17.9 times by its yearly operating cash.
Higher than 89% of Healthcare companies in United States.
Cash Cushion Ratio
+0%Cash, after subtracting all debt, equals 0% of its market value (net cash).
Lower than 67% of Healthcare companies in United States.
Tangible Assets Ratio
99%Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 91% of Healthcare companies in United States.
Tangible Net Worth Ratio
99%Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 93% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
ADMA Biologics, Inc. owes $0.40 for every $1 it owns. Net profit fell 26% in the year to Dec 2025.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
15.6Investors pay $15.6 for every $1 of ADMA Biologics, Inc.'s yearly profit, lower than 73% of Healthcare companies in United States.
P/B ratio
6.01The share price is 6.01 times ADMA Biologics, Inc.'s book value per share, higher than 77% of Healthcare companies in United States.
Market cap
$2.5 BThe total market value of all of ADMA Biologics, Inc.'s shares at today's price (share price × number of shares), larger than 78% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$408 MWhat ADMA Biologics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.82Net worth divided by the number of shares. The share price of $10.95 is 6.0 times this, which is the P/B above.
Return on equity (ROE)
41.9%ADMA Biologics, Inc. earned 41.9% on its shareholders' money over the last year, higher than 96% of Healthcare companies in United States.
Owes vs Owns
0.40×ADMA Biologics, Inc. owes $0.40 for every $1 it owns (low), lower than 51% of Healthcare companies in United States.
Dividend yield
NoneADMA Biologics, Inc. does not currently pay a dividend.
Revenue growth
+20%Revenue rose 20% in the year to Dec 2025, and grew 49% a year on average over 3 years.
Profit growth
-26%Net profit fell 26% in the year to Dec 2025.
Profit margin
28.8%ADMA Biologics, Inc. keeps $29 of every $100 of revenue as net profit.
Cash quality
0.3×Cash from ADMA Biologics, Inc.'s business was 0.3× its reported profit in the year to Dec 2025 — less cash came in than the profit reported.
Interest cover
26.9×ADMA Biologics, Inc.'s operating profit covered its interest costs 26.9 times in the year to Dec 2025.
Cash vs debt
Net cashADMA Biologics, Inc. held $8 M more cash than debt (net cash) at Dec 2025.
Questions
What is ADMA Biologics, Inc.'s P/E ratio?
Investors pay $15.6 for every $1 of ADMA Biologics, Inc.'s yearly profit, lower than 73% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For ADMA Biologics, Inc.: $2.5 B ÷ $408 M (30 Jun 2026) = 6.0.
What is ADMA Biologics, Inc.'s return on equity?
ADMA Biologics, Inc. earned 41.9% on its shareholders' money over the last year, higher than 96% of Healthcare companies in United States.
How much does ADMA Biologics, Inc. owe compared with what it owns?
ADMA Biologics, Inc. owes $0.40 for every $1 it owns (low), lower than 51% of Healthcare companies in United States.
Does ADMA Biologics, Inc. pay a dividend?
No. ADMA Biologics, Inc. does not currently pay a dividend.
Is ADMA Biologics, Inc.'s revenue growing?
Revenue rose 20% in the year to Dec 2025, and grew 49% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.